Published online Feb 28, 2021. doi: 10.3748/wjg.v27.i8.677
Peer-review started: November 11, 2020
First decision: December 17, 2020
Revised: December 24, 2020
Accepted: January 21, 2021
Article in press: January 21, 2021
Published online: February 28, 2021
Core Tip: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Without effective treatment, NAFLD can progress to fibrosis, cirrhosis, and liver cancer. Currently, there is no effective treatment option. G protein-coupled receptors (GPCRs) have been shown to play essential roles in metabolic disorders, such as NAFLD, through their function as receptors for bile acids and free fatty acids. Therapies such as probiotics and GPCR agonists could be applied to modulate GPCR function to ameliorate liver metabolism syndrome. Herein, this review summarizes the current findings regarding the role of GPCRs in the development and progression of NAFLD.